Haplotype block structure of the genomic region of the mu opioid receptor gene

Journal of Human Genetics

Volumn 56, Issue 2, 2011, Pages 147-155

  Levran, Orna ^a   Awolesi, Olaoluwakitan ^a   Linzy, Shirley ^b   Adelson, Miriam ^b   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b Dr Miriam and Sheldon G Adelson Clinic for Drug Abuse Treatment and Research   (United States)

Author keywords

distal 5 region; genetic variations; haplotype; LD blocks; opioid addiction

Indexed keywords

MU OPIATE RECEPTOR;

ARTICLE; GENETIC ANALYSIS; GENETIC VARIABILITY; HAPLOTYPE; HUMAN;

ALLELES; CASE-CONTROL STUDIES; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC VARIATION; GENOME; GENOTYPE; HAPLOTYPES; HUMANS; INTRONS; LINKAGE DISEQUILIBRIUM; MULTICENTER STUDIES AS TOPIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; REFERENCE VALUES; REGULATORY SEQUENCES, NUCLEIC ACID;

EID: 79952147741     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1038/jhg.2010.150     Document Type: Article

References (42)

1. Oertel, B. G., Kettner, M., Scholich, K., Renne, C., Roskam, B., Geisslinger, G. et al. A common human mu-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J. Biol. Chem. 284, 6530-6535 (2009).
2. Wand, G. S., McCaul, M., Yang, X., Reynolds, J., Gotjen, D., Lee, S. et al. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26, 106-114 (2002). (Pubitemid 34075281)
3. Hernandez-Avila, C. A., Covault, J., Wand, G., Zhang, H., Gelernter, J. & Kranzler, H. R. Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation. Pharmacogenet Genomics 17, 1031-1038 (2007). (Pubitemid 351339487)
4. Hernandez-Avila, C. A., Wand, G., Luo, X., Gelernter, J. & Kranzler, H. R. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am. J. Med. Genet B. Neuropsychiatr. Genet 118, 60-65 (2003). (Pubitemid 37064077)
5. Bart, G., Heilig, M., LaForge, K. S., Pollak, L., Leal, S. M., Ott, J. et al. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol. Psychiatry 9, 547-549 (2004).
6. Kapur, S., Sharad, S., Singh, R. A. & Gupta, A. K. A118g polymorphism in mu opioid receptor gene (oprm1): association with opiate addiction in subjects of Indian origin. J. Integr. Neurosci. 6, 511-522 (2007).
7. Bart, G., Kreek, M. J., Ott, J., LaForge, K. S., Proudnikov, D., Pollak, L. et al. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 30, 417-422 (2005). (Pubitemid 40129493)
8. Glatt, S. J., Bousman, C., Wang, R. S., Murthy, K. K., Rana, B. K., Lasky-Su, J. A. et al. Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. Drug Alcohol Depend 90, 159-165 (2007). (Pubitemid 47299168)
9. Levran, O., Londono, D., O'Hara, K., Nielsen, D. A., Peles, E., Rotrosen, J. et al. Genetic susceptibility to heroin addiction: a candidate gene association study. Genes Brain Behav. 7, 720-729 (2008).
10. Walter, C. & Lotsch, J. Meta-analysis of the relevance of the OPRM1 118A4G genetic variant for pain treatment. Pain 146, 270-275 (2009).
11. Skorpen, F., Laugsand, E. A., Klepstad, P. & Kaasa, S. Variable response to opioid treatment: any genetic predictors within sight? Palliat Med 22, 310-327 (2008). (Pubitemid 351895347)
12. Kosarac, B., Fox, A. A. & Collard, C. D. Effect of genetic factors on opioid action. Curr. Opin. Anaesthesiol. 22, 476-482 (2009).
13. Kreek, M. J., Bart, G., Lilly, C., LaForge, K. S. & Nielsen, D. A. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol. Rev. 57, 1-26 (2005). (Pubitemid 40283968)
14. Birney, E., Stamatoyannopoulos, J. A., Dutta, A., Guigo, R., Gingeras, T. R., Margulies, E. H. et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447, 799-816 (2007). (Pubitemid 46920138)
15. Xu, J., Xu, M., Hurd, Y. L., Pasternak, G. W. & Pan, Y. X. Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene. J. Neurochem. 108, 962-972 (2009).
16. Pan, Y. X., Xu, J., Mahurter, L., Xu, M., Gilbert, A. K. & Pasternak, G. W. Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X. Biochem. Biophys. Res. Commun. 301, 1057-1061 (2003). (Pubitemid 36279220)
17. Pan, Y. X. Identification of alternatively spliced variants from opioid receptor genes. Methods Mol. Med. 84, 65-75 (2003).
18. Pan, L., Xu, J., Yu, R., Xu, M. M., Pan, Y. X. & Pasternak, G. W. Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience 133, 209-220 (2005). (Pubitemid 40694171)
19. Choi, H. S., Kim, C. S., Hwang, C. K., Song, K. Y., Wang, W., Qiu, Y. et al. The opioid ligand binding of human mu-opioid receptor is modulated by novel splice variants of the receptor. Biochem. Biophys. Res. Commun. 343, 1132-1140 (2006).
20. Shabalina, S. A., Zaykin, D. V., Gris, P., Ogurtsov, A. Y., Gauthier, J., Shibata, K. et al. Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum. Mol. Genet. 18, 1037-1051 (2009).
21. Abbadie, C., Pan, Y. X. & Pasternak, G. W. Immunohistochemical study of the expression of exon11-containing mu opioid receptor variants in mouse brain. Neuroscience 127, 419-430 (2004). (Pubitemid 38950657)
22. Pan, Y. X., Xu, J., Mahurter, L., Bolan, E., Xu, M. & Pasternak, G. W. Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene. Proc. Natl Acad. Sci. USA 98, 14084-14089 (2001). (Pubitemid 33116028)
23. Pan, Y. X. Identification and characterization of a novel promoter of the mouse mu opioid receptor gene (Oprm) that generates eight splice variants. Gene 295, 97-108 (2002).
24. Kleinjan, D. A. & Lettice, L. A. Long-range gene control and genetic disease. Adv. Genet 61, 339-388 (2008).
25. Bayerer, B., Stamer, U., Hoeft, A. & Stuber, F. Genomic variations and transcriptional regulation of the human mu-opioid receptor gene. Eur. J. Pain 11, 421-427 (2007). (Pubitemid 46366768)
26. Hoehe, M. R., Kopke, K., Wendel, B., Rohde, K., Flachmeier, C., Kidd, K. K. et al. Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum. Mol. Genet 9, 2895-2908 (2000).
27. Luo, X., Kranzler, H. R., Zhao, H. & Gelernter, J. Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am. J. Med. Genet B. Neuropsychiatr. Genet 120, 97-108 (2003). (Pubitemid 37059385)
28. Hodgkinson, C. A., Yuan, Q., Xu, K., Shen, P. H., Heinz, E., Lobos, E. A. et al. Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. Alcohol Alcohol 43, 505-515 (2008).
29. Zhang, H., Luo, X., Kranzler, H. R., Lappalainen, J., Yang, B. Z., Krupitsky, E. et al. Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum. Mol. Genet 15, 807-819 (2006). (Pubitemid 43338224)
30. Zhang, D., Shao, C., Shao, M., Yan, P., Wang, Y., Liu, Y. et al. Effect of mu-opioid receptor gene polymorphisms on heroin-induced subjective responses in a Chinese population. Biol. Psychiatry 61, 1244-1251 (2007). (Pubitemid 46726256)
31. Levran, O., Londono, D., O'Hara, K., Randesi, M., Rotrosen, J., Casadonte, P. et al. Heroin addiction in African Americans: a hypothesis-driven association study. Genes Brain Behav. 8, 531-540 (2009).
32. Nielsen, D. A., Ji, F., Yuferov, V., Ho, A., Chen, A., Levran, O. et al. Genotype patterns that contribute to increased risk for or protection from developing heroin addiction. Mol. Psychiatry 13, 417-428 (2008). (Pubitemid 351399824)
33. Taylor, J., Tyekucheva, S., King, D. C., Hardison, R. C., Miller, W. & Chiaromonte, F. ESPERR: learning strong and weak signals in genomic sequence alignments to identify functional elements. Genome. Res. 16, 1596-1604 (2006). (Pubitemid 44878498)
34. Pritchard, J. K., Stephens, M. & Donnelly, P. Inference of population structure using multilocus genotype data. Genetics 155, 945-959 (2000).
35. Enoch, M. A., Shen, P. H., Xu, K., Hodgkinson, C. & Goldman, D. Using ancestryinformative markers to define populations and detect population stratification. J. Psychopharmacol 20, 19-26 (2006). (Pubitemid 44576654)
36. Barrett, J. C., Fry, B., Maller, J. & Daly, M. J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005). (Pubitemid 40202029)
37. Rozen, S. & Skaletsky, H. Primer3 on the WWW for general users and for biologist programmers. Methods. Mol. Biol. 132, 365-386 (2000).
38. Adoue, V., Chavanas, S., Coudane, F., Mechin, M. C., Caubet, C., Ying, S. et al. Longrange enhancer differentially regulated by c-Jun and JunD controls peptidylarginine deiminase-3 gene in keratinocytes. J. Mol. Biol. 384, 1048-1057 (2008).
39. Coop, G., Pickrell, J. K., Novembre, J., Kudaravalli, S., Li, J., Absher, D. et al. The role of geography in human adaptation. PLoS Genet 5, e1000500 (2009).
40. Arias, A., Feinn, R. & Kranzler, H. R. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend 83, 262-268 (2006).
41. Xuei, X., Flury-Wetherill, L., Bierut, L., Dick, D., Nurnberger Jr, J., Foroud, T et al. The opioid system in alcohol and drug dependence: family-based association study. Am. J. Med. Genet B. Neuropsychiatr. Genet 144, 877-884 (2007). (Pubitemid 47547987)
42. Oroszi, G., Anton, R. F., O'Malley, S., Swift, R., Pettinati, H., Couper, D. et al. OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol. Clin. Exp. Res. 33, 383-393 (2009).